Our Partnerships and Collaborations
By balancing our internal research and product development with academic collaboration and corporate partnering, we have the opportunity to advance our PLE delivery platform and our promising pipeline of oncology product candidates.
We are collaborating with Avicenna Oncology GmbH, a leading antibody drug conjugate development company based in Basel, Switzerland, to focus on the development of new PDCs by combining our patented phospholipid ether delivery platform with Avicenna's novel cytotoxic warheads (potent anti-cancer small molecules). Those novel cytotoxic warheads were previously attempted to be made as antibody drug conjugates, and were unsuccessful.
Orano Med (formerly AREVA Med) is a nuclear medicine biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing recognizing and destroying cancer cells while limiting the impact on nearby healthy cells. With its partners, Orano Med pursues the development of effective therapies to address patient needs. Orano Med is a subsidiary of Orano.